Metronomic Chemotherapy: Changing the Paradigm That More is Better

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2009 Apr 17

PMID 19370174

Citations 66

Authors

O G Scharovsky

L E Mainetti

V R Rozados

Affiliations

Soon will be listed here.

Abstract

The introduction of the "maximum tolerated dose" in usual treatment protocols (and its concomitant overt toxicity) made necessary the imposition of rest periods between cycles of therapy-a practice that not only involves re-growth of tumour cells, but also growth of selected clones resistant to the therapy. To avoid the problems caused by traditional chemotherapeutic regimens, a new modality of drug administration called "metronomic chemotherapy" has been proposed. This name makes reference to the chronic, equally spaced administration of (generally) low doses of various chemotherapeutic drugs without extended rest periods. The novelty of this treatment modality lies not only in its antitumour efficacy with very low toxicity, but also in a cell target switch, now aiming at tumour endothelial cells. The knowledge acquired in the experimental field of metronomic chemotherapy, plus the increasing experience that is being obtained in the clinical setting, will help to lead a change in the design of therapeutic protocols against cancer.

Citing Articles

Metronomic Chemotherapy After Palliative Radiotherapy in Rare Soft Tissue Sarcomas: An Insight into Radiation Therapy and the Immune Response.

Madabhavi I, Sarkar M, Sagar R Indian J Surg Oncol. 2024; 15(4):677-683.

PMID: 39555377 PMC: 11564421. DOI: 10.1007/s13193-024-01966-2.

A doxorubicin loaded chitosan-poloxamer implant for the treatment of breast cancer.

Sahoo G, Rai V, Pradhan D, Halder J, Rajwar T, Mahanty R RSC Adv. 2024; 14(46):33952-33967.

PMID: 39463476 PMC: 11503159. DOI: 10.1039/d4ra06253a.

The Complex Tumor Microenvironment in Ovarian Cancer: Therapeutic Challenges and Opportunities.

Garlisi B, Lauks S, Aitken C, Ogilvie L, Lockington C, Petrik D Curr Oncol. 2024; 31(7):3826-3844.

PMID: 39057155 PMC: 11275383. DOI: 10.3390/curroncol31070283.

Metronomic chemotherapy: bridging theory to clinical application in canine and feline oncology.

Petrucci G, Magalhaes T, Dias M, Queiroga F Front Vet Sci. 2024; 11:1397376.

PMID: 38903691 PMC: 11187343. DOI: 10.3389/fvets.2024.1397376.

Optimizing cancer therapy: a review of the multifaceted effects of metronomic chemotherapy.

Basar O, Mohammed S, Qoronfleh M, Acar A Front Cell Dev Biol. 2024; 12:1369597.

PMID: 38813084 PMC: 11133583. DOI: 10.3389/fcell.2024.1369597.

References

Young S, Whissell M, Noble J, Cano P, Lopez P, Germond C . Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors. Clin Cancer Res. 2006; 12(10):3092-8. DOI: 10.1158/1078-0432.CCR-05-2255. View

Caballero M, Grau J, Blanch J, Domingo-Domenech J, Auge J, Jimenez W . Serum vascular endothelial growth factor as a predictive factor in metronomic (weekly) Paclitaxel treatment for advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2007; 133(11):1143-8. DOI: 10.1001/archotol.133.11.1143. View

Spieth K, Kaufmann R, Gille J . Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. Cancer Chemother Pharmacol. 2003; 52(5):377-82. DOI: 10.1007/s00280-003-0678-9. View

Bocci G, Tuccori M, Emmenegger U, Liguori V, Falcone A, Kerbel R . Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann Oncol. 2005; 16(8):1243-52. DOI: 10.1093/annonc/mdi240. View

Man S, Bocci G, Francia G, Green S, Jothy S, Hanahan D . Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. 2002; 62(10):2731-5. View

Colleoni M, Orlando L, Sanna G, Rocca A, Maisonneuve P, Peruzzotti G . Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol. 2005; 17(2):232-8. DOI: 10.1093/annonc/mdj066. View

Munoz R, Man S, Shaked Y, Lee C, Wong J, Francia G . Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res. 2006; 66(7):3386-91. DOI: 10.1158/0008-5472.CAN-05-4411. View

Klauber N, Parangi S, Flynn E, Hamel E, DAmato R . Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 1997; 57(1):81-6. View

Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F . Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood. 2001; 97(11):3658-61. DOI: 10.1182/blood.v97.11.3658. View

10.

Capillo M, Mancuso P, Gobbi A, Monestiroli S, Pruneri G, Dellagnola C . Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clin Cancer Res. 2003; 9(1):377-82. View

11.

Garcia A, Hirte H, Fleming G, Yang D, Tsao-Wei D, Roman L . Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008; 26(1):76-82. DOI: 10.1200/JCO.2007.12.1939. View

12.

Takahashi N, Haba A, Matsuno F, Seon B . Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res. 2001; 61(21):7846-54. View

13.

Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T . Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997; 275(5302):964-7. DOI: 10.1126/science.275.5302.964. View

14.

Klement G, Huang P, Mayer B, Green S, Man S, Bohlen P . Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res. 2002; 8(1):221-32. View

15.

Lord R, Nair S, Schache A, Spicer J, Somaihah N, Khoo V . Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol. 2007; 177(6):2136-40. DOI: 10.1016/j.juro.2007.01.143. View

16.

Orlando L, Cardillo A, Ghisini R, Rocca A, Balduzzi A, Torrisi R . Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer. 2006; 6:225. PMC: 1579231. DOI: 10.1186/1471-2407-6-225. View

17.

Coleman M, Martin P, Ruan J, Furman R, Niesvizky R, Elstrom R . Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma. Leuk Lymphoma. 2008; 49(3):447-50. DOI: 10.1080/10428190701837330. View

18.

Soffer S, Moore J, Kim E, Huang J, Yokoi A, Manley C . Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor. J Pediatr Surg. 2001; 36(8):1177-81. DOI: 10.1053/jpsu.2001.25747. View

19.

Emmenegger U, Man S, Shaked Y, Francia G, Wong J, Hicklin D . A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res. 2004; 64(11):3994-4000. DOI: 10.1158/0008-5472.CAN-04-0580. View

20.

Shiraga E, Barichello J, Ishida T, Kiwada H . A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model. Int J Pharm. 2007; 353(1-2):65-73. DOI: 10.1016/j.ijpharm.2007.11.020. View